Prescription of Testosterone-Lowering Medications for Sex Offender Treatment in German Forensic-Psychiatric Institutions

Journal of Sexual Medicine

Volumn 10, Issue 2, 2013, Pages 570-578

  Turner, Daniel ^a   Basdekis Jozsa, Raphaela ^a   Briken, Peer ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Cyproterone acetate; GnRH agonist; Paraphilia; Sex offender; Treatment guidelines

Indexed keywords

CYPROTERONE ACETATE; GONADORELIN AGONIST; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SALVACYL; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE; TRIPTORELIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE DENSITY; CHILD SEXUAL ABUSE; DEPRESSION; DRUG INDUCED DISEASE; FORENSIC PSYCHIATRY; GERMANY; GYNECOMASTIA; HAIR LOSS; HOT FLUSH; HUMAN; HYPOGONADISM; INJECTION SITE PAIN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOTHERAPY; QUESTIONNAIRE; RAPE; SEXUAL BEHAVIOR; SEXUAL CRIME; SIDE EFFECT; THROMBOEMBOLIA; WEIGHT GAIN;

EID: 84873057195     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2012.02958.x     Document Type: Article

References (53)

1. Foote R. Hormone treatment of sex offenders. J Nerv Ment Dis 1944;99:928-29.
2. Golla FL, Hodge SR. Hormone treatment of sexual offenders. Lancet 1949;253:1006-07.
3. Whittaker LH. Oestrogen and psychosexual disorder. Med J Aust 1959;46:547-49.
4. Eher R, Gnoth A, Birklbauer A, Pfäfflin F. Antiandrogene Medikation zur Senkung der Rückfälligkeit von Sexualstraftätern: Ein kritischer Überblick. Recht und Psychiatrie 2007;25:103-11.
5. Hebebrand K, Hebebrand J, Remschmidt H. Medikamente in der Behandlung von Paraphilien und hypersexuellen Störungen. Fortschr Neurol Psychiatr 2002;70:462-75.
6. Laschet U, Laschet L. Antiandrogentherapie der pathologisch gesteigerten und abartigen Sexualität des Mannes. Klin Wschr 1967;45:324-5.
7. Laschet U, Laschet L. Psychopharmacotherapy of sex offenders with cyproteron acetate. Pharmakopsychiatr Neuropsychopharmakol 1971;4:99-104.
8. Cooper AJ. A placebo-controlled trial of the anti-androgen cyproteron acetate in deviant hypersexuality. Compr Psychiatry 1981;22:458-65.
9. Cooper AJ, Cernovovsky Z. The effect of cyproterone acetate on sleeping and waking penile erections in pedophiles: Possible implications for treatment. Can J Psychiatry 1992;37:33-9.
10. Meyer WJ III, Cole C, Emory E. Depo provera treatment for sex offending behavior: An evaluation of outcome. Bull Am Acad Psychiatry Law 1992;20:249-59.
11. Bradford JM, Pawlak A. Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Arch Sex Behav 1993;22:629-41.
12. Rösler A, Witztum E. Pharmacotherapy of paraphilias in the next millenium. Behav Sci Law 2000;18:43-56.
13. Czerny J-P, Briken P, Berner W. Antihormornal treatment of paraphilic patients in German forensic psychiatric clinics. Eur Psychiatry 2002;17:104-6.
14. Hill A, Briken P, Kraus C, Strohm K, Berner W. Differential pharmacological treatment of paraphilias and sex offenders. Int J Offender Ther Comp Criminol 2003;47:407-21.
15. Jordan K, Fromberger P, Stolpman G, Müller JL. The role of testosterone in sexuality and paraphilia-A neurobiological approach. Part II: Testosterone and paraphilia. J Sex Med 2011;8:3008-29.
16. Li J, Al Azzawi F. Mechanism of androgen receptor action. Maturitas 2009;63:142-8.
17. Leranth C, Petnehazy O, MacLusky NJ. Gonadal hormones affect spine synaptic density in the CA1 hippocampal subfield of male rats. J Neurosci 2003;23:1588-92.
18. Abdelgadir SE, Roselli CE, Choate JV, Resko JA. Androgen receptor messenger ribonucleic acid in brains and pituitaries of male rhesus monkeys: Studies on distribution, hormonal control, and relationship to luteinizing hormone secretion. Biol Reprod 1999;60:1251-6.
19. Guay DRP. Drug treatment of paraphilic and nonparaphilic sexual disorders. Clin Ther 2009;31:1-31.
20. Allolio B, Keffel D, Deuss U, Winkelmann W. Behandlung sexueller Verhaltensstörungen mit LHRH Superagonisten. Dtsch Med Wochenschr 1985;110:1952.
21. Briken P, Nika E, Berner W. Treatment of paraphilia with luteinizing hormone-releasing hormone agonists. J Sex Marital Ther 2001;27:45-55.
22. Jordan K, Fromberger P, Stolpman G, Müller JL. The role of testosterone in sexuality and paraphilia-A neurobiological approach. Part I: Testosterone and sexuality. J Sex Med 2011;8:2993-3007.
23. Rösler A, Witztum E. Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. N Engl J Med 1998;338:416-22.
24. Briken P, Hill A, Berner W. Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: A systematic review. J Clin Psychiatry 2003;64:890-7.
25. Safarinejad MR. Treatment of nonparaphilic hypersexuality in men with a long-acting analog of gonadotropin-releasing hormone. J Sex Med 2008;6:1151-64.
26. Schiffer B, Gizewski E, Kruger T. Reduced neuronal responsiveness to visual sexual stimuli in a pedophile treated with a long-acting LH-RH agonist. J Sex Med 2009;6:892-4.
27. Thibaut F, Cordier B, Kuhn JM. Gonadotropin hormone releasing hormone agonist in cases of severe paraphilia: A lifetime treatment? Psychoneuroendocrinology 1996;21:411-9.
28. Thibaut F, Barra FDL, Gordon H, Cosyns P, Bradford JMW. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the biological treatment of paraphilias. World J Biol Psychiatry 2010;11:604-55.
29. Krueger RB, Kaplan MS. The paraphilic and hypersexual disorders: An overview. J Psychiatr Pract 2001;7:391-403.
30. Hoogeveen J, Van der Veer E. Side effects of pharmacotherapy on bone with long-acting gonadorelin agonist triptorelin for paraphilia. J Sex Med 2008;5:626-30.
31. Briken P, Kafka MP. Pharmacological treatment for paraphilic patients and sexual offenders. Curr Opin Psychiatry 2007;20:609-13.
32. Gooren LJ. Ethical and medical considerations of androgen deprivation treatment of sex offenders. J Clin Endocrinol Metab 2011;96:3628-37.
33. Lösel F, Schmucker M. The effectiveness of treatment for sexual offenders: A comprehensive meta-analysis. J Exp Criminol 2005;1:117-46.
34. Briken P, Welzel K, Habermann N, Hill A, Berner W. Antiandrogene Therapie und Lockerungen bei Sexualstraftätern im Maßregelvollzug Berlin. Psychiatr Prax 2009;36:232-7.
35. Meyer WJ, Cole CM. Physical and chemical castration of sex offenders: A review. J Offender Rehabil 1997;25:1-18.
36. Berner W, Hill A, Briken P, Kraus C, Lietz K. DGPPN-Leitlinien Störungen der Sexualpräferenz. Darmstadt: Steinkopff; 2007.
37. McGrath RJ, Cumming GF, Burchard BL, Zeoli S, Ellerby L. Current practices and emerging trends in sexual abuser management: The Safer Society 2009 North American survey. Brandon, Vermont: Safer Society Press; 2010.
38. Bundeskriminalamt. Die Kriminalität in der Bundesrepublik Deutschland: Polizeiliche Kriminalstatistik 2010. Berlin: Bundesministerium des Inneren; 2011.
39. Hahn G. Psychisch kranke Straftäter. In: Cornel H, Kawamura-Reindl K, Maelicke B, Sonnen BR, eds. Resozialisierung. Handbuch. Baden-Baden: Nomos; 2009:390-405.
40. Hahn G, Worthmüller M. Forensische Nachsorgeambulanzen in Deutschland. Patientenstruktur, Interventionsformen und Verlauf in der Nachsorge psychisch kranker Straftäter nach Entlassung aus dem Maßregelvollzug gem. §63 StGB. Daten der Stichtagserhebung Forensische Fachambulanzen 2009. In: Pauls H, Reicherts M, Schlittmaier A, eds. Schriftenreihe zur psychosozialen Gesundheit: Beiträge zur klinischen Sozialarbeit. Coburg: IPSG; 2011.
41. Pozsár C, Schlichting M, Krukenberg J. Sexualstraftäter in der Maßregelbehandlung: Ergebnisse einer Stichtagserhebung in Niedersachsen. Monatsschr Kriminol 1999;82:94-103.
42. Rossegger A, Endrass J, Urbaniok F, Vetter S, Maercker A. From victim to offender: Characteristics of sexually abused violent and sex offenders. Nervenarzt 2011;82:866-72.
43. Langevin R, Langevin M, Curnoe S, Bain J. The prevalence of diabetes among sexual and violent offenders and its co-occurrence with cognitive impairment, mania, psychotic symptoms and aggressive behavior. Int J Prison Health 2008;4:83-95.
44. Raymond NC, Coleman E, Ohlerking F, Christenson GA, Miner M. Psychiatric comorbidity in pedophilic sex offenders. Am J Psychiatry 1999;156:786-8.
45. Dunsieth NW Jr, Nelson EB, Brusman-Lovins LA, Holcomb JL, Beckman D, Welge JA, Roby D, Taylor P Jr, Soutullo CA, McElroy SL. Psychiatric and legal features of 113 men convicted of sexual offenses. J Clin Psychiatry 2004;65:293-300.
46. Dolan M, Millington J, Park I. Personality and neuropsychological function in violent, sexual and arson offenders. Med Sci Law 2002;42:34-43.
47. Dickey R. The management of a case of treatment-resistant paraphilia with long-acting LHRH agonist. Can J Psychiatry 1992;37:567-9.
48. Gottesman H, Yokley J, Sloam D. The use of leuprolide acetate in the treatment of four types of paraphilia. 16th Annual Research and Treatment Conference of the Association for the Treatment of Sexual Abusers October 1997 Arlington, VA; 1997.
49. Kraus C, Strohm K, Hill A, Habermann N, Berner W, Briken P. Selective serotonine reuptake inhibitors (SSRI) in the treatment of paraphilia. Fortschr Neurol Psychiatr 2007;75:351-6.
50. Raymond NC, Grant JE, Coleman E. Augmentation with naltrexone to treat compulsive sexual behavior: A case series. Ann Clin Psychiatry 2010;22:56-62.
51. Bradford JMW. The neurobiology, neuropharmacology, and pharmacological treatment of the paraphilias and compulsive sexual behavior. Can J Psychiatry 2001;46:26-34.
52. Ryback RS. Naltrexone in the treatment of adolescent sexual offenders. J Clin Psychiatry 2004;65:982-6.
53. Pfäfflin F. Sexualstraftaten. In: Foerster K, Dreßing H, eds. Psychiatrische Begutachtung. Ein praktisches Handbuch für Ärzte und Juristen. München: Urban & Fischer; 2009:330-60.